WebParithera’s goal is to save lives by providing a minimally invasive diagnostic which analyses cancer treatment resistance and allows clinicians to adjust treatment regimen. Activity or Research Description: Development of CTC liquid biopsy technologies with single cell … Web11 Apr 2024 · Cancer Therapy Evaluation Program study 9557 (ClinicalTrials.gov identifier NCT02097225) is a phase 1 study that was designed to assess the safety and efficacy of the small-molecule HSP90 inhibitor, AT13387, in combination with dabrafenib and trametinib in BRAF V600E/K –mutant solid tumors.
Parithera raises CHF 100 000 from FIT - BioAlps
WebParithera Signals Growth Rate 0.80% Weekly Growth Weekly Growth 0.80%, 93rd % -35.5%. 530% Size Multiple 219x Median Size Multiple 219x, 100th %ile 0.00x 0.95x. 413Kx Key … Web26 Nov 2024 · Parithera receives an Innogrant The EPFL Tech Launchpad is pleased to announce they have granted an award of CHF100,000 to Parithera – an EPFL-startup which improves the efficacy of cancer … other wave bluetooth
CHF 100’000 for Parithera ExTrace Dx Cancer Tracking
WebExplore Parithera's alternatives and competitors. Medicor Biosciences. Medicor Biosciences, founded in 2006 is a development-stage company focused on drug discovery for combating cancer. Web8 Dec 2024 · See Parithera funding rounds, investors, investments, exits and more. Evaluate their financials based on Parithera's post-money valuation and revenue. Parithera Stock … WebParithera . Connect to CRM . Save . Summary Financials People Technology Signals & News Similar Companies. Highlights. Active Tech Count 17. About. Parithera is actively using 17 technologies for its website, according to BuiltWith. These include Viewport Meta, IPhone / Mobile Compatible, and SPF. other way agency